Management Of Acute Disseminating Encephalomyelitis

Acute Disseminated Encephalomyelitis Clinical Trial

Official title:

Management of Acute Disseminated Encephalomyelitis in Neurology Unit of Assiut University Children Hospital

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03284801
• Other study ID #: ADEM
• Status: Not yet recruiting
• Phase: N/A
• First received: September 8, 2017
• Last updated: September 13, 2017
• Start date: January 2018
• Est. completion date: March 2019

Study information

• Verified date: September 2017
• Source: Assiut University
• Contact: Farouk Alsayed hassanen, prof
• Phone: 01006178123
• Email: Farouk.hassan[@]med.eu.edu.eg
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute disseminated encephalomyelitis is an immune-mediated inflammatory demyelinating disease of the central nervous system, which is typically transitory and self-limiting. It is characterized by an acute or subacute encephalopathy with neurological deficits, and magnetic resonance imaging evidence of widespread demyelination that predominantly involves the white matter of the brain and spinal cord. In the absence of specific biological markers, the diagnosis of Acute disseminated encephalomyelitis is still based upon a combination of clinical and neuro imaging features and exclusion of diseases that mimic Acute disseminated encephalomyelitis

Description:

Acute disseminated encephalomyelitis can occur at any age, but usually affects children and young adults. The mean age of clinical presentation in pediatric cohorts ranges from 5 to 8 years. The annual incidence of Acute disseminated encephalomyelitis is reported to be 0.4-0.8 per 100,000 and the disease more commonly affects children and young adults, probably related to the high frequency of exanthematous and other infections and vaccination in this age group.Initial symptoms and signs of Acute disseminated encephalomyelitis usually begin within 2 days to 4 weeks after a viral infection or vaccination, and include a rapid onset encephalopathy (behavioral change or altered consciousness) associated with a combination of multifocal neurological deficits, leading to hospitalization within a week. Typically Acute disseminated encephalomyelitis presents with systemic symptoms such as fever, malaise, headache, nausea, and vomiting, which may occur shortly before the appearance of neurological signs and symptoms. The clinical course is rapidly progressive, developing maximum deficits within a few days (mean 4.5 days) . A wide variety of neurological deficits have been described in pediatric patients with Acute disseminated encephalomyelitis, including: obtundation and depressed consciousness (invariable); unilateral or bilateral long tract signs (60-95%); acute hemiplegia (76%); ataxia (18-59%); meningismus (26-31%); seizures (13-35%); spinal cord involvement (24%); visual involvement (7-23%); and speech impairment or aphasia (5-21%). Cerebellar mutism and prolonged focal motor seizures in the context of Acute disseminated encephalomyelitis have been mainly reported in children younger than 5 years of age.Acute combined peripheral nervous system demyelination is not rare in children with Acute disseminated encephalomyelitis whereas it is more frequently described in adult patients, with a reported frequency of 44% in one study. A particular Acute disseminated encephalomyelitis phenotype affecting young children has been reported in association with group A beta hemolytic streptococcal infection. Prominent behavioral disturbances, dystonic movements, and basal ganglia abnormalities on MRI (in addition to typical white matter lesions) characterize this syndrome.

Supportive care in the acute stage is critical and early antiviral treatment with acyclovir (30 mg/kg/ day) is highly recommended on admission, considering that viral encephalitis and particularly herpes simplex encephalitis is the usual primary diagnosis in a child with fever, encephalopathy, seizures, and focal neurological signs. The treatment for Acute disseminated encephalomyelitis includes primarily the management of acute attacks. Corticosteroid treatment at high doses is the most widely reported therapy. Most authors recommend a brief (3-5 days) high-dose intravenous steroid course, usually methylprednisolone given at 20-30 mg/kg/day to a maximum dose of 1 g/day, or dexamethasone given at 1 mg/kg/day, followed by oral prednisone taper for 4-6 weeks . Reported treatment approaches show a wide variety in the specific steroid formulation employed, as well as in the dosing, routes of administration, and tapering regimens. Treatment with corticosteroids requires careful monitoring of blood pressure, urine glucose, and serum potassium, and administration of gastric protection. The use of immunoglobulin has been reported in several case studies either alone or in combination with corticosteroids. The recommended total dose of immunoglobulin is 2 g/kg, administered over 2-5 days. The usefulness of immunoglobulin has been reported both as a second-line treatment in steroid-unresponsive Acute disseminated encephalomyelitis cases and in patients showing recurrent or steroid-dependent demyelination.

The use of plasma exchange has been recently established as possibly effective and it may be considered as escalation therapy for steroid-unresponsive acute fulminant demyelinating diseases including Acute disseminated encephalomyelitis, multiple sclerosis, and transverse myelitis, . Plasmapheresis should be started as soon as the treatment failure is recognized. The use of this procedure in Acute disseminated encephalomyelitis has been reported in only a small number of severe cases. A median number of seven exchanges (range 2 to 20) were reported in one study. Moderate to severe anemia, symptomatic hypotension, hypocalcemia, potential transfusion reactions or transmission of transfusion-related diseases, and heparin-associated thrombocytopenia have been described in relation to therapeutic plasma exchange. There is also a risk of catheter-related complications, including thrombosis, septic infections or pneumothorax.

Acute hemorrhagic leukoencephalitis is often considered the most acute and severe form of Acute disseminated encephalomyelitis, with a universally fatal course within hours to days after the onset of neurological symptoms without treatment. Survival in pediatric patients has been reported with combined therapy including high-dose intravenous corticosteroid, immunoglobulin, Therapeutic plasma exchange, and decompressive craniotomies. Aggressive treatment strategies such as surgical decompression have to be considered and performed in patients with fulminant variants of Acute disseminated encephalomyelitis, with evidence of continued clinical deterioration due to increased intracranial pressure, unresponsive to conventional medical treatment and critical care measures.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: March 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Months to 18 Years

Eligibility

Inclusion Criteria:

• All patient presented with manifestation of acute disseminating encephalomyelitis admitted in Assiut University Children Hospital

Exclusion Criteria:

• Patients presented with viral encephalitis,bacterial meningitis

• Cases not fulfilling MRI criteria for diagnosis of acute disseminated encephalomyelitis

Related Conditions & MeSH terms

• Acute Disseminated Encephalomyelitis
• Encephalomyelitis

Intervention

Other:
• management of acute disseminating encephalomyelitis
clinical audit on management of acute disseminating encephalomyelitis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (9)

Anlar B, Basaran C, Kose G, Guven A, Haspolat S, Yakut A, Serdaroglu A, Senbil N, Tan H, Karaagaoglu E, Karli Oguz K. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics. 2003 Aug;34(4):194-9. — View Citation

Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294-300. doi: 10.1212/WNL.0b013e318207b1f6. Review. — View Citation

Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000 Dec;123 Pt 12:2407-22. — View Citation

Hynson JL, Kornberg AJ, Coleman LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001 May 22;56(10):1308-12. — View Citation

Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002 Jan 8;58(1):143-6. — View Citation

Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stüve O. Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol. 2007 Jun;20(3):247-54. Review. — View Citation

Pohl D, Tenembaum S. Treatment of acute disseminated encephalomyelitis. Curr Treat Options Neurol. 2012 Jun;14(3):264-75. doi: 10.1007/s11940-012-0170-0. — View Citation

Tenembaum S, Chitnis T, Ness J, Hahn JS; International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology. 2007 Apr 17;68(16 Suppl 2):S23-36. Review. — View Citation

Wingerchuk DM. Postinfectious encephalomyelitis. Curr Neurol Neurosci Rep. 2003 May;3(3):256-64. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	clinical audit on management of acute disseminating encephalomyelitis	To improve diagnosis and management of acute disseminated encephalomyelitis in Neurology Unit of Assiut University Children Hospital and to decrease the mortality and residual deficits from this disease.; The aim of this audit is to measure the current practice within the Neurology Unit of Assiut University Children Hospital team in the diagnosis and management of acute disseminated encephalomyelitis against the recommendations in American Academy of Neurology guidance by using checklist and designed questionnaire.	within one year